Edition:
United Kingdom

Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

125.82USD
20 Nov 2018
Change (% chg)

-- (--)
Prev Close
$125.82
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
123,393
52-wk High
$220.09
52-wk Low
$77.60

Chart for

About

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and... (more)

Overall

Beta: --
Market Cap(Mil.): $4,400.80
Shares Outstanding(Mil.): 3.26
Dividend: --
Yield (%): --

Financials

  BGNE.OQ Industry Sector
P/E (TTM): -- 83.63 33.59
EPS (TTM): -4.93 -- --
ROI: -57.59 -0.64 15.05
ROE: -77.45 0.08 16.62

Chinese biotech BeiGene raises $903 million in HK's first secondary listing under new rules: sources

HONG KONG (Reuters/IFR) - Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong - the first under new exchange rules - near the top of an indicative range, three people close to the deal said on Thursday.

02 Aug 2018

Chinese biotech BeiGene raises $903 million in Hong Kong's first secondary listing under new rules - sources

HONG KONG (Reuters/IFR) - Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong - the first under new exchange rules - near the top of an indicative range, three people close to the deal said on Thursday.

02 Aug 2018

UPDATE 1-Chinese biotech BeiGene raises $903 mln in HK's first secondary listing under new rules -sources

* Deal is second under new rules for early-stage biotechs (Adds deal details, context)

02 Aug 2018

Chinese biotech BeiGene raises $903 mln in HK's first secondary listing under new rules -sources

HONG KONG, Aug 2 (Reuters/IFR) - Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong - the first under new exchange rules - near the top of an indicative range, three people close to the deal said on Thursday.

02 Aug 2018

Earnings vs. Estimates